The only patented “nano-particle delivery system” to transport cannabis directly into the bloodstream drives interest

The medicinal industries have created many secondary businesses and products that go on to be huge successes.

NanoSphere Health Sciences Inc. (CSE: NSHS) is a nano biotechnology company paving the way in the development of innovative delivery systems for cannabinoids, medications, nutrients, and animal health. The Company provides the only patented “nano-particle delivery system” to transport therapeutic agents directly into the bloodstream for maximum absorbency. The Company’s initial focus has been on cannabis delivery systems.

Evolve Formulas – A nano-particle delivery system for cannabis

NanoSphere’s Evolve Formulas is the provider of the world’s first and only scientifically proven nano-particle delivery system for cannabis. NanoSphere’s Evolve Formulas and applicators are very unique in the way they deliver medicinal cannabis to the body. By encapsulating cannabinoid molecules in lipid membranes, they are transported through the skin and into the bloodstream within minutes. NanoSphere’s delivery system makes particles easy to absorb and completely bypasses the gastrointestinal tract. No more need for needles or swallowing horrible medicines.

NanoSphere’s delivery systems

On October 10 2018, NanoSphere announced that it has entered the next phase of its partnership with Vertical™, the largest fully integrated company in the legal medical cannabis industry. Official production has started to bring its commercial cannabis brand, Evolve Formulas, into the California market.

Robert Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve Formulas said: “We’re thrilled to break ground and enter the next phase of our partnership with industry leader Vertical by bringing our patented technology to the world’s largest legal cannabis market. With California representing nearly a third of the North American cannabis market, the commencement of production in this powerhouse state marks an enormous step for the Evolve Formulas brand in our national expansion strategy.”

Vertical™ recently presented Evolve™ to a trade show for the California legal cannabis industry. J. Smoke Wallin, President of Vertical said: “Evolve stood out for its unique value proposition to patients everywhere. This has led to a backlog of pre-orders from accounts waiting for us to launch with California compliant packaging in November. The market can’t wait!”

Evolve Formulas is currently available in over 200 dispensaries in Colorado, with hemp-based products soon to launch in Indiana. California is the first of numerous markets across the country to begin manufacturing the Evolve Formulas products under NanoSphere Health Sciences’ licensing partnership with Vertical.

NanoSphere has already partnered with Delta 9 Cannabis INC to bring products from its cannabis brand, Evolve Formulas, into the Canadian market.

Future markets next for NanoSphere

NanoSphere’s first push has been into cannabis delivery; however Nanosphere also has several other potential markets it plans to tap into in the future as shown in the graphic below.

NanoSphere’s potential markets

NanoSphere certainly ticks all the right boxes. They have an in demand (and award winning) product for cannabis delivery, and can expand across other sectors delivering pharmaceuticals, over the counter medicines, dietary supplements and animal health products. The runway for potential future growth is huge. One to follow.




Move over Fantasy Football, the Cannabis Market just got very real.

Forget the Fall sport season because if you haven’t been watching the Cannabis Breakfast Club, we have some awe-inspiring numbers that may get you on-side and looking at stock charts with your morning coffee. Yesterday, we published To be a Billionaire or not? The Canadian Cannabis Breakfast Club struggles with U.S. border entry concerns where we address the significant challenges arising from border crossing concerns for Canadian executives and investors alike entering the U.S.

Speaking of entry am I the only suffering from the colossal cannabis market envy and interested in whether there is room to still enjoy what appears to be a bud bull market?

While Terry Booth of Aurora Cannabis Inc. (TSX: ACB | OTCQB: ACBFF) had been a client in 2015, I recall attending meetings for financings and listening as bankers would explain why they were not interested in cannabis…. this column is dedicated to all of us that could have, should have but maybe didn’t… and more importantly is it too late?

Wince forward.

If we had bought $100k in Aurora Cannabis stock on January 2, 2015 at $0.40, as of market close last night at $10.87, our stock would be worth $2,717,500.

Taking one more step backwards into the past, imagine that we had invested this same fantasy $100k in the 4 leaders in the Canadian Cannabis Breakfast Club in 2015…. what may we have been worth this morning?

Let’s break it down.

Hypothetically, we would have bought 12,195 shares of Canopy Growth Corporation (TSX: WEED) at $2.05, which closed at $63.40 today, market cap $14.5B – and acquired 62,500 shares of Aurora Cannabis Inc. (TSX: ACB) at $0.40, they closed at $10.87 today, market cap $10.35B. Then perhaps we would have selected 23,810 shares of Aphria Inc. (TSX: APH) at $1.05, they closed at $19.28 today, market cap $4.48B. And finally, scoring 31,646 shares of Cronos Group Inc. (TSX: CRON) at $0.79, they closed at $16.25 – market cap $2.87B. And voila, our fantasy 100k would be today worth nearly $2.5M this morning ($2,426,574.00) — a stunning 2326.57% lift in 33 months!

Wow.

Now where are we today? I ask an the CEO of CannaIncome Fund Arthur Kwan – is it too late? He responds: “With Tilray (NASDAQ: TLRY) reaching an intra-day high of US$300 and closing at US$214 today, the mass hysteria surrounding cannabis stocks continues. With a market capitalization of US$20 billion, it is hard to fathom that Tilray, in a matter of a few short months since going public, is now larger than Canopy Growth (TSX: WEED) and other well-known brands, including WhirlPool, Harley-Davidson, and Hyatt Hotels.

While there is no doubt that this is a very over-heated market, we continue to believe that there’s value in this sector, although now you may have to dig a little harder to find that hidden gem. We see opportunities in the next ‘wave’ of growth companies as we get closer to legalization in Canada including edibles, beverages, and biosynthesis.”

He tells me that CannaIncome is maintaining their market advantage by “investing in the early pre-IPO rounds at significant discounts to public company valuations.”

InvestorIntel Editor Matthew Bohlsen provided us with the following updates on half a dozen cannabis sector companies that are advertisers on InvestorIntel. The companies are listed by market cap, these numbers were taken from TD Waterhouse on September 20, 2018.

WeedMD Inc. (TSXV: WMD), $228.04M Market Cap: WeedMD Inc. is a Canadian licensed producer and distributor of cannabis with large production facilities in Canada. The Company recently announced it has completed the export of its cannabis genetics to Australia’s Medifarm.

Edward Harris, Managing Director of Medifarm, said: “Medifarm prides itself on the cultivation of exclusive cannabis genetics, supported by proven breeding programs used in university and hospital clinical trials for therapeutic use. WeedMD’s highly regarded cannabis strains will help us bring Australians continued access to a diverse set of consistent, quality cannabis products, ensuring that our patients have access to clinically validated and cost-effective medicine for their therapeutic use is paramount for Medifarm.”

Early in September 2018, WeedMD announced it has now completed the first harvest from its modern greenhouse in Strathroy, Ontario. The Company marked the event with a WeedMD “First Harvest” celebration party, a community open house that welcomed well over 120 guests that included WeedMD’s Board of Directors, local government, business leaders, investors, media representatives and employees.

Keith Merker, CEO of WeedMD said: “We’re proud to have been able to share this important milestone with our community, stakeholders, employees and industry. The first harvest was completed in early September and resulted in an impressive yield from our first 10,000 square foot grow room.”

I am guessing it must have been a great party, and I hope to get an invitation to the next one as this WeedMD is having great success both in Canada and soon in Australia.

Scythian Biosciences Corp. (CSE: SCYB | OTC – Nasdaq Intl: SCCYF), $173.9M Market Cap: Scythian Biosciences Corp. is an international cannabis company with a focus on the burgeoning U.S. medical cannabis marketplace. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States’ medical cannabis industry.

Scythian has initiated its international expansion by launching additional cannabis related activities across the globe. The Company is evaluating several strategic initiatives and pursuing partnerships with local cultivators, pharmaceutical import and distribution entities and universities in North America, South America, Caribbean and beyond.

Just as any area of the body begins to swell after impact and injury due to inflammation, brain tissue itself does as well. Unfortunately, because the brain is confined inside the skull, the inflammation naturally triggered ends up causing even more damage as the process continually pushes already-injured brain tissue against bone. For contact sports players, repeated concussions can have devastating effects later in life. Cannabinoids are an effective treatment for mild brain trauma (concussions). This is going to be great news for professional sports organizations involved in contact sports and should hopefully lead to wide spread adoption for Scythian’s therapy and products.

Viridium Pacific Group Ltd. (TSXV: VIR), $44.82M Market Cap: Viridium Pacific Group Ltd. is a Canadian producer of medical cannabis products. It is proceeding to meet the health Canada requirements to amend its current producer license to include a license to sell. The Company is involved in consumer wellness and biotech innovation, with interests spanning across agricultural production, property development, and financial services.

Viridium Pacific is positioned to develop and expand into new markets across multiple platforms. Earlier this year, a subsidiary of Viridium, Experion Bio-technologies acquired 25 new cannabis strains from a renowned Dutch supplier, increasing the number of strains available from 2 to 27. The new cannabis strains acquired by Experion are proprietary strains developed in one of the most sophisticated breeding programs in the world.

Viridium has signed a Letter of Intent (September 13, 2018) with Montreal Medical Cannabis Inc. (“MMCI”) to establish a partnership in Pointe Claire, Quebec. With only 9 of 116 Canadian license producers headquartered in the province, Quebec represents a significant opportunity for Viridium to establish licensed cannabis cultivation and distribution. Viridium Pacific will provide expertise to help prepare the MMCI facility for Health Canada inspections, and expedite the application process under its licensed subsidiary, Experion Biotechnologies Inc. The facility currently under renovation is 76,000 square feet with an anticipated output of cannabis over 10,000 kg per year. On October 17, 2018, Canada is to become the third nation in the world to formally legalize cannabis for recreational use and become the first G7 nation to do so. Viridium are in a perfect position in a fast-growing industry with new legislation ready to take effect.

NanoSphere Health Sciences Inc. (CSE: NSHS) Market Cap $37.66M: NanoSphere Health Sciences Inc.’s Evolve Formulas product is the provider of the world’s first and only scientifically proven nano particle delivery system for cannabis. For those that can remember the original Star Trek series, the Evolve product administers directly into the system in a similar way to the Doctor on the Enterprise administered medicine. They called it a hypo-spray. This cutting edge technology eliminates the need for inhalation or ingestion of cannabis, offering users a safer and more effective method of consumption.

The onset time of cannabinoids delivered by the NanoSphere Delivery System™ is just 10 minutes, thereby relieving the user from pain and anxiety in an extremely short period of time. NanoSphere was recognized as Company of the Year for Nano Biotechnology and Innovative, Company of the Year for Healthcare, and three 2018 Global Awards from ACQ5, a premier global corporate magazine. NanoSphere has partnered with Delta 9 Cannabis INC to bring products from its cannabis brand, Evolve Formulas, into the Canadian market, under an agreement, that will see a 50/50 net revenue share from sale of Evolve Formulas products.

The NanoSphere Delivery System could be an ideal way to deliver vitamins, minerals, super-nutrients into the system as well as eliminate the use for needles to deliver medicines. That’s got to make parents and kids very happy.

Global Cannabis Applications Corp. (CSE: APP | OTCQB: FUAPF), $20.22M Market Cap: Global Cannabis Applications Corp.  (“GCAC”) goal is to build a technology-enabled community to improve the health and wellness of medical patients and users alike. The Company has created the Citizen Green Community, a database that uses a mobile app platform for subscribers to interact with other medicinal cannabis users to share benefits, knowledge and personal experiences from their use.

Their Prescriptii app is designed to help patients find the appropriate products for their medical condition. It allows patients to easily rate the cannabis products they have been prescribed, learn about products that have helped other patients, and provide feedback about the effectiveness.

The Company’s CannaLife app was designed to create conversation, share ideas, and promote education on a single social platform (the Cannabis Facebook?). Real conversations will take place showing users what is trending, who to follow, tag, subscribe, and communities to join. Users can also lead the conversation by creating their own communities or sharing information by taking a snapshot from a web page.

With the Prescriptii and CannaLife apps, and the Citizen Green data platform, GCAC is establishing a leadership position by using science and advance technology to gain important insight into the medical cannabis industry. Because of legislation, data on cannabis use and its effects hasn’t really existed for obvious reasons (who wanted it known that you were a user). Now GCAC is giving medicinal users the chance to record and share experiences on the Company’s Citizen Green apps.

CO2 GRO Inc. (TSXV: GROW), $10.62M Market Cap: CO2 GRO Inc.’s (“GROW”) mission is to accelerate all outdoor and indoor plants naturally, safe and economically using its patented advanced CO2 foliar spray technologies. Recent trials are proof of this, with results on CO2 foliar spray versus CO2 gassing. Spraying dissolved CO2 to the top as well as the bottom of a lettuce leaf is more effective in stimulating dramatically faster plant growth and plant size/mass than CO2 gassing. This also proves why GROW’s CO2 Foliar Spray technology integrated into advanced irrigation boom trials are showing sharply faster and larger plant growth.

CEO John Archibald noted: “This additional St. Cloud State University discovery and success integrating our CO2 technology into irrigation spray booms provides further evidence of the commercial potential of our technology. Our revenue generation model is long term site technology licenses and lease of our integration equipment in both indoor and outdoor boom spray systems.”

In August, CO2 GRO conducted their second cannabis trial with a positive commercial indoor trial. The second trial was on a leafier indicia strain that yielded an estimated 60% increase in bud value whereas the first trial on a stringier sativa strain yielded an estimated 45% increase. CO2 GRO’s Indica cannabis trial bud weight increased 20%, was grown 20% faster and had 75% more THC than the control bud group.

It is kind of amazing when you think how this could possibly solve food shortage problems and create a stronger cannabis strain. More food is going to be needed globally each year, and CO2 GRO can play an important role.




A revolutionary nano-particle delivery system for cannabis provides a Star Trek moment

NanoSphere Health Sciences Inc. (CSE: NSHS) (“NanoSphere”) is a nano-biotechnology company based in Greenwood Village, Colorado, USA. NanoSphere is a company paving the way in the development of innovative delivery systems for cannabinoids, medications, nutrients, and animal health. The Company provides the only patented nano-particle delivery system to transport the highest level of therapeutic agents directly to the bloodstream for maximum absorbency.

Evolve Formulas – Transdermal NanoSerum

NanoSphere’s Evolve Formulas is the provider of the world’s first and only scientifically proven nano-particle delivery system for cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSphere’s delivery system makes particles easy to absorb and completely bypasses the gastrointestinal tract and respiratory system. Only 6% of edible cannabis and 20% smoking cannabis enters the body.

Nanosphere Evolve product

NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing.

Now I am thinking, I have seen this on an episode of Star Trek. In the world of Star Trek, there’s no need for needles as the Doctor administers medicine through the skin using a painless jet-injected hypo-spray. Considering this is a TV series from the 1960s, several futuristic ideas are already commercially viable on today’s market – The cell phone (Flip Phone), laptops and tablet computers, 3D printers (replicators, still waiting for the food version though), large screen TVs and much more.

The comparison on the left is Nanosphere’s Evolve product and on the right is Star Trek’s hypo-spray

NanoSpehere is winning technology innovation awards

In recognition of the innovative and disruptive work the company is doing, NanoSphere has been recognized with a nomination from the National Cannabis Industry Association (NCIA) for the Excellence in Technology award in infused products and extraction. The award is granted to a company that has developed a new technology that will have a lasting effect on the industry. NanoSphere Chief Science Officer Dr. Richard Kaufman said: “It comes as no surprise to us that our technology is being recognized for its market disruption. We are proud of our achievements so far in the nano-particle delivery space and look forward to advancing our technology with new applications and new markets.” This delivery platform, was also recently awarded the Frost and Sullivan 2018 Best Practices Award for Technological Innovation.

Cannabis marijuana leaf

In recent news (July 31, 2018), NanoSphere announced they had entered into a partnership with Delta 9 Cannabis INC to bring products from its cannabis brand, Evolve Formulas, into the Canadian market. Delta 9 shares NanoSphere’s vision for bringing innovative and reliable products to market for recreational and medical consumers alike in the only G7 nation that has legalized cannabis for both purposes. Under the agreement, Delta 9 and NanoSphere will each receive 50 percent of the net revenue from sale of Evolve Formulas products. The initial term of the agreement is 36 months following the date of the first commercial sale of licensed products. Delta 9 is a licensed producer of marijuana and operates an 80,000 square foot production facility in Winnipeg, Canada.

NanoSphere Health Sciences Inc. has a market cap of C$ 42 m. The Company is only just now starting commercial sales of their products, so revenue figures will start to follow soon.

How many of today’s innovators have been inspired by the Star Trek TV show. This technology has the potential to change the way medicine is delivered efficiently to the body. It will have needle phobia people and parents dancing in the street. The potential for the Company to expand into new markets is enormous. So for now investors can look to buy some shares in NanoSphere, watch some more Star Trek shows, and keep a close eye on the progress of NanoSphere.




Scythian CEO on the potential impact of cannabinoid drugs on traumatic brain injuries

Jonathan Gilbert, CEO and Director, and David Schrader, COO of Scythian Biosciences Corp. (TSXV: SCYB) (“Scythian”) in an interview with InvestorIntel Senior Editor Peter Clausi discuss the cannabinoid drug Scythian has developed to treat traumatic brain injuries. David states the drug is for immediate use after impact “to try and prevent” continuing brain damage, tissue damage from inflammation and any additional damage from the body’s own immune response. Scythian has partnered with the “world renowned” University of Miami Medical Center, who will be completing the preclinical and clinical testing of Scythian’s cannabinoid drug.

Peter Clausi: Today we are discussing Scythian Biosciences Corp., a biotech company doing research in the cannabinoid space. Could you tell us something about the company?

David Schrader: This company started out in the medical marijuana field in Canada, and has a license application pending. About 2 years ago we changed into the drug development sector where we are focusing on drugs that are marijuana related, cannabinoids and we have one drug currently in testing at the University of Miami.

Peter Clausi: What drug are you testing?

David Schrader: We are testing a drug…It is a combination drug for traumatic brain injury. Whenever somebody gets a head injury, aside from the initial impact, there is a lot of tissue damage that happens after the actual injury.

Peter Clausi: This is what the NFL, CFL and the NHL have been addressing with their concussion protocols. Is that right?

David Schrader: It is, but a lot of the focus on the football arena really is the cumulative effect, CTE, that take place over a long period of time. Our drug is focused on immediately after an impact to try and prevent continuing brain damage that occurs, tissue damage from inflammation and from the body’s own immune response immediately after an injury.

Peter Clausi: You mentioned you are doing research with the University of Miami. Why Miami?

David Schrader: University of Miami Medical Center and the hospital have an amazing staff. They have a division that actually is world renowned, one of the top couple in the country that focuses on brain and spinal cord injuries. We have a team of some of the top doctors in the country who are specialists in different areas relating to brain injuries and spinal cord injuries… to access the complete interview, click here

Disclaimer: Scythian Bioscience Corp. is an advertorial member of InvestorIntel.